Postmarket Safety

FDA Expands Opioid Prescription REMS to IR Formulations

Manufacturers of short-acting opioids will be required to offer the kind of doctor training in administering the medications that their extended-release counterparts have been directed to provide since 2012, FDA Commissioner Scott Gottlieb said. Read More